Stockscreener 앱 받기
16.82
4.81%
-0.85
시간 외 거래:
16.81
-0.01
-0.06%
Cadrenal Therapeutics Inc 주식(CVKD)의 최신 뉴스
Cadrenal Takes Center Stage: Key Executives to Showcase Novel Anticoagulant at Industry-Leading Events - Stock Titan
Q1 Earnings Estimate for CVKD Issued By Zacks Small Cap - Defense World
(CVKD) Trading Advice - Stock Traders Daily
Altimmune to put its incretin into addiction trials; Tarsus aims to raise $125M - Endpoints News
Cadrenal Therapeutics Advances Tecarfarin Development in 2024 - TipRanks
Cadrenal Therapeutics Reports Full Year 2024 Results - TradingView
Cadrenal Therapeutics, Inc. SEC 10-K Report - TradingView
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin - Bluefield Daily Telegraph
Cadrenal Secures FDA Orphan Drug Status and Abbott Partnership for Breakthrough Phase 3 Trial - StockTitan
CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial - Research Tree
(CVKD) Technical Pivots with Risk Controls - Stock Traders Daily
Cadrenal and Abbott sign agreement for LVAD trial of tecarfarin - Yahoo Finance
Cadrenal Therapeutics teams with Abbott inTECH-LVAD trial - TipRanks
Abbott Laboratories (NYSE:ABT) Partners With Cadrenal Therapeutics For TECH-LVAD Trial In Growing US$2B LVAD Market - Yahoo Finance
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD - BioSpace
Cadrenal Therapeutics to Collaborate With Abbott on Trial of Heart Device Drug -March 04, 2025 at 08:53 am EST - Marketscreener.com
Cadrenal Therapeutics Announces Collaboration Agreement With Abbott -March 04, 2025 at 08:14 am EST - Marketscreener.com
Cadrenal Therapeutics (CVKD) Projected to Post Earnings on Monday - The AM Reporter
Cadrenal Therapeutics (CVKD) Expected to Announce Earnings on Monday - Defense World
CVKD stock hits 52-week high at $20.79 amid robust growth By Investing.com - Investing.com South Africa
CVKD stock hits 52-week high at $20.79 amid robust growth - Investing.com India
(CVKD) Trading Signals - Stock Traders Daily
Cadrenal Therapeutics Announces New Chief Medical Officer in Recent SEC Filing - Defense World
Biondi becomes managing partner at Flagship - BioCentury
Cadrenal Therapeutics Appoints New Chief Medical Officer - TipRanks
Clinical Trials News Live Feed - StockTitan
Cadrenal Therapeutics appoints new chief medical officer - MSN
Cadrenal Therapeutics appoints new chief medical officer By Investing.com - Investing.com UK
Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin - Business Wire
Former Amgen & AstraZeneca Executive Takes Helm of Revolutionary Anticoagulation Drug Development - Stock Titan
Cadrenal Therapeutics to Present at BIO CEO & Investor Conference - BioSpace
Revolutionary Warfarin Alternative Takes Center Stage: Cadrenal CEO to Unveil Latest Tecarfarin Data - StockTitan
(CVKD) Investment Report - Stock Traders Daily
Cadrenal Therapeutics (NASDAQ:CVKD) Trading 14.3% Higher – Time to Buy? - Defense World
Ponte Vedra-based Cadrenal CEO Quang Pham talks biotech, funding - The Business Journals
Learn to Evaluate (CVKD) using the Charts - Stock Traders Daily
Ponte Vedra biotech firm opens the Nasdaq - The Business Journals
(CVKD) Long Term Investment Analysis - Stock Traders Daily
Cadrenal Therapeutics CEO to Present Breakthrough Anticoagulant at Lytham Healthcare Summit - StockTitan
Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - BioSpace
Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Expands By 5.7% - Defense World
Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications - Business Wire
AT&T (NYSE:T) Price Target Raised to $30.00 - Defense World
Cadrenal Therapeutics (NASDAQ:CVKD) Shares Up 11.6% – Time to Buy? - Defense World
Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility - The Eastern Progress Online
CVKDCadrenal Therape Latest Stock News & Market Updates - StockTitan
Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings - Business Wire
Cadrenal Therapeutics to Showcase Novel Anticoagulant Tecarfarin at J.P. Morgan Healthcare Conference - Stock Titan
(CVKD) Trading Report - Stock Traders Daily
What is Zacks Small Cap’s Estimate for CVKD FY2024 Earnings? - Defense World
1.23%
1.63%
자본화:
|
볼륨(24시간):